Analysts Update Ratings on Healthcare Stocks: Ultragenyx Strong Buy, Immutep Downgraded
Analysts updated ratings on healthcare stocks: Ultragenyx remains Strong Buy, Immutep downgraded to Hold, BridgeBio gets Buy. American Well and Baxter stay Hold. Upside ranges from 11% to 154%.
Analysts issued new ratings and price targets on several healthcare companies, including Ultragenyx Pharmaceutical, Immutep, American Well, BridgeBio Pharma, and Baxter International. Ultragenyx retained a Strong Buy consensus across multiple firms, while Immutep was downgraded to Hold.
Ultragenyx Pharmaceutical received repeated Buy ratings. Wells Fargo maintained a Buy with a $45.00 price target, J.P. Morgan maintained a Buy, Bank of America Securities reiterated a Buy, and Morgan Stanley maintained a Buy with a $50.00 target. The analyst consensus on the stock is Strong Buy, with average price targets ranging from $54.32 to $57.71, representing upside of 140.9% to 154.5% from recent closing levels.
Immutep was downgraded to Hold by Maxim Group. The company's shares closed last Friday at $0.48. The general analyst consensus rating for Immutep is Hold.
BridgeBio Pharma received a new Buy rating from Bernstein with a $94.00 price target. The company's shares closed last Thursday at $76.06. The consensus is Strong Buy with an average price target of $100.69, implying 18.7% upside. TD Cowen also maintained a Buy with a $95.00 target.
American Well was reiterated a Hold by Needham, with shares closing last Thursday at $4.33. The consensus is Hold with a price target of $5.33, representing 22.0% upside. BTIG also maintained a Hold.
Baxter International was maintained at Hold by Bank of America Securities, with shares closing last Friday at $19.75. The consensus is Hold with an average price target of $20.70, representing 10.9% upside. Stifel Nicolaus also maintained a Hold with a $20.00 target.